United Therapeutics Corp.
Vice President, Xeno and Regenerative Medicine Operations
Matthew VonEsch serves as the Vice President of Xeno and Regenerative Medicine Operations at United Therapeutics, a Public Benefit Corporation (PBC) with a purpose of providing a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Beginning with Wyeth Biopharma, followed by Human Genome Sciences, MedImmune, United Therapeutics, and Exelead; he has held positions of increasing responsibility in drug substance and drug product manufacturing. His expertise encompasses upstream and downstream biologics processing, aseptic vial filling, automated inspection, labeling and packaging operations, and most recently end to end organ manufacturing. A recognized leader in advanced aseptic technologies, Matthew is the former Chair of the ISPE Sterile Products Processing COP Steering Committee and has served as an author and reviewer for numerous baseline guidance documents. In 2018, he returned to United Therapeutics to focus on solid/whole organ manufacturing for direct human transplantation with the hopes of solving the critical shortage of organs for transplantation. Matthew holds a BS in Biochemistry from the Merrimack College.
